AR035564A1 - Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos - Google Patents

Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos

Info

Publication number
AR035564A1
AR035564A1 ARP010100372A ARP010100372A AR035564A1 AR 035564 A1 AR035564 A1 AR 035564A1 AR P010100372 A ARP010100372 A AR P010100372A AR P010100372 A ARP010100372 A AR P010100372A AR 035564 A1 AR035564 A1 AR 035564A1
Authority
AR
Argentina
Prior art keywords
administration
strogens
strogen
receivers
combination
Prior art date
Application number
ARP010100372A
Other languages
English (en)
Original Assignee
Endorech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endorech Inc filed Critical Endorech Inc
Publication of AR035564A1 publication Critical patent/AR035564A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Métodos novedosos para reducir o eliminar la incidencia de accesos de calor y síntomas menopáusicos, que al mismo tiempo disminuyen el riesgo de adquirir cáncer de mama o de endometrio y para tratar y/o inhibir además el desarrollo de osteoporosis, hipercolesterolemia, hiperlipidemia, ateroesclerosis, hipertensión, resistencia a insulina, diabetes, pérdida de masa muscular, obesidad, irregularidades menstruales, enfermedad de Alzheimer o sequedad vaginal en animales de sangre caliente susceptibles, inclusive seres humanos que comprende la administración de un modulador selectivo de receptores de estrógeno, en particular compuestos que presentan la estructura general (1) y una cantidad de un estrógeno o un compuesto estrogénico / androgénico mixto. Además, se describe específicamente la administración de bifosfonatos, progestágeno o un precursor de esteroides sexuales para el tratamiento médico y/o la inhibición de algunas de las enfermedades mencionadas anteriormente. También se describen composiciones farmacéuticas para la distribución del o de los ingredientes activos y uno o varios conjuntos de elementos (''kits'') de utilidad para la presente.
ARP010100372A 2000-01-28 2001-01-26 Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos AR035564A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17860100P 2000-01-28 2000-01-28

Publications (1)

Publication Number Publication Date
AR035564A1 true AR035564A1 (es) 2004-06-16

Family

ID=22653187

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100372A AR035564A1 (es) 2000-01-28 2001-01-26 Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos

Country Status (21)

Country Link
US (3) US20020198179A1 (es)
EP (1) EP1251855A1 (es)
JP (1) JP2003520817A (es)
KR (1) KR20020073566A (es)
CN (1) CN1400904A (es)
AR (1) AR035564A1 (es)
AU (1) AU2991301A (es)
BR (1) BR0108107A (es)
CA (1) CA2395730A1 (es)
CZ (1) CZ20022401A3 (es)
HK (1) HK1048761A1 (es)
HU (1) HUP0204211A3 (es)
IL (1) IL149990A0 (es)
MX (1) MXPA02007165A (es)
NO (1) NO20023484D0 (es)
NZ (1) NZ534348A (es)
PL (1) PL357163A1 (es)
RU (1) RU2342145C2 (es)
SK (1) SK9592002A3 (es)
WO (1) WO2001054699A1 (es)
ZA (1) ZA200205926B (es)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012623A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
BR0112360A (pt) * 2000-07-06 2003-05-06 Wyeth Corp Método para aumentar a atividade da sintase de óxido nìtrico
WO2002003988A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist / antagonist to produce a drug for the treatment of vaginitis
US7276250B2 (en) * 2001-07-06 2007-10-02 Penwest Pharmaceuticals Company Sustained release formulations of oxymorphone
PL367094A1 (en) * 2001-07-31 2005-02-21 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
TW200307553A (en) * 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
ATE344025T1 (de) * 2002-06-06 2006-11-15 Hormos Medical Ltd Behandlung oder prävention von urogenitaler atrophie und deren symptomen bei frauen
MXPA05000824A (es) * 2003-05-23 2005-04-28 Akzo Nobel Nv Forma de dosis farmaceutica de liberacion inmediata que contiene tibolona polimorfa.
WO2005073190A1 (en) * 2004-01-29 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US7601855B2 (en) 2004-09-21 2009-10-13 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
MX2007004830A (es) * 2004-10-20 2007-10-04 Endorech Inc Precursores esteroides sexuales solos o en combinacion con un modulador receptor de estrogeno selectivo y/o con estrogenos y/o con un inhibidor de fosfodiesterasa gmpc de tipo 5 para la prevencion y tratamiento de resequedad vaginal y disfuncion sexu
AU2006214515A1 (en) * 2005-02-16 2006-08-24 Wyeth Use of estrogen receptor-b selective agonists for radiation-or chemotherapy-induced mucosistis and radiation cystitis
BRPI0711525A2 (pt) 2006-06-02 2011-11-01 Pear Tree Women S Health Care composição farmacêutica e método para tratar sintomas de vaginite atrófica
US8933130B2 (en) * 2006-06-23 2015-01-13 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
WO2008101030A1 (en) * 2007-02-13 2008-08-21 The Regents Of The University Of California Methods for amplifying steroid hormone effects
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
ES2524002T3 (es) 2007-02-14 2014-12-03 Forendo Pharma Ltd. Método para la preparación de derivados de trifenilbuteno con valor terapéutico
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
US20140040862A1 (en) * 2008-04-03 2014-02-06 Adobe Systems Incorporated Copying Reusable Components from a Remote Source
AU2014201406B2 (en) * 2009-06-16 2016-08-11 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
AU2016235019B2 (en) * 2009-06-16 2018-06-28 Endorecherche, Inc. Treatment of alzheimer's disease, loss of cognition, memory loss, and dementia with sex steroid precursors in combination with selective estrogen receptor modulators
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
LT2568806T (lt) 2010-05-12 2016-09-26 Radius Health, Inc. Terapiniai režimai
PL2580210T3 (pl) 2010-06-10 2017-09-29 Seragon Pharmaceuticals, Inc. Modulatory receptora estrogenowego i ich zastosowania
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
EP2635121B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014014124A2 (pt) 2011-12-14 2017-08-22 Seragon Pharmaceutical Inc Moduladores do receptor de estrogênio fluorados e usos dos mesmos
CN104169266A (zh) 2011-12-16 2014-11-26 奥乐玛药物股份有限公司 新的苯并吡喃化合物、其组合物和用途
CN102584687A (zh) * 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
CA2864104A1 (en) * 2012-02-14 2013-08-22 Repros Therapeutics Inc. Selective estrogen receptor modulators with short half-lives and uses thereof
CN102631677A (zh) * 2012-04-19 2012-08-15 中国农业大学 一种预防和/或治疗动脉粥样硬化的药物组合物
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JP6174156B2 (ja) 2012-10-19 2017-08-02 フェルミオン オサケ ユキチュア オスペミフェンの製造方法
JP2015535283A (ja) 2012-11-02 2015-12-10 レプロス セラピューティクス インコーポレイティド 癌療法における使用のためのトランス−クロミフェン
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
EP3834824A1 (en) 2014-03-28 2021-06-16 Duke University Method of treating cancer using selective estrogen receptor modulators
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
HUE054998T2 (hu) 2015-02-02 2021-10-28 Mei Pharma Inc Kombinációs terápiák emlõrák kezelésében való alkalmazásra
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2018071440A1 (en) 2016-10-11 2018-04-19 Duke University Treatment of breast cancer
WO2018129419A1 (en) 2017-01-05 2018-07-12 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
US10729650B2 (en) * 2017-01-23 2020-08-04 United States Of America As Represented By The Secretary Of The Air Force Skin punch biopsy and wound-debridgement training model
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
US5446061A (en) * 1993-11-05 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5446071A (en) * 1994-11-18 1995-08-29 Eli Lilly And Company Methods for lowering serum cholesterol
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
ATE206701T1 (de) * 1996-04-19 2001-10-15 American Home Prod Östrogene verbindungen
AR017256A1 (es) * 1997-08-21 2001-09-05 American Home Prod Compuestos de indol sustituidos, metodo para la sintesis en fase solida de los mismos, conjuntos de combinacion para ser empleados en dicho metodo, uso delos compuestos para preparar un medicamento y composiciones farmaceuticas que los comprenden
US6465445B1 (en) * 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) * 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
DE19916419B4 (de) * 1999-04-08 2005-06-16 Schering Ag Kombinationspräparat aus Vitamin-D-Metaboliten oder Vitamin-D-Analoga und einem Östrogenpartialagonisten zur Behandlung von Osteoporose
CN1390126B (zh) * 1999-07-06 2012-06-13 恩多研究公司 选择性雌激素受体调节剂在制备用于治疗或降低肥胖症发展危险性的药物中的用途

Also Published As

Publication number Publication date
CZ20022401A3 (cs) 2003-10-15
HUP0204211A3 (en) 2005-06-28
AU2991301A (en) 2001-08-07
SK9592002A3 (en) 2003-12-02
US20020198179A1 (en) 2002-12-26
US20030040510A1 (en) 2003-02-27
NO20023484L (no) 2002-07-22
NZ534348A (en) 2006-06-30
CN1400904A (zh) 2003-03-05
MXPA02007165A (es) 2003-09-22
BR0108107A (pt) 2003-03-11
ZA200205926B (en) 2003-07-24
JP2003520817A (ja) 2003-07-08
NO20023484D0 (no) 2002-07-22
RU2342145C2 (ru) 2008-12-27
IL149990A0 (en) 2002-12-01
RU2002123047A (ru) 2004-03-10
CA2395730A1 (en) 2001-08-02
HUP0204211A2 (hu) 2003-04-28
PL357163A1 (en) 2004-07-26
KR20020073566A (ko) 2002-09-27
EP1251855A1 (en) 2002-10-30
WO2001054699A1 (en) 2001-08-02
HK1048761A1 (zh) 2003-04-17
US20030065008A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
AR035564A1 (es) Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos
US5719136A (en) Combination of progesterone antagonists and antiestrogens with partial agonistic action for hormone substitution therapy for perimenopausal and postmenopausal women
CA2334702C (en) Pharmaceutical compositions and uses for androst-5-ene-3.beta.,17.beta.-diol
ES2200384T3 (es) Medio anticonceptivo hormonal.
US10201611B2 (en) Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
US20040072808A1 (en) Treatment of conditions relating to hormone deficiencies by administration of progestins
DE60307602T2 (de) Kontinuierliche sulfatase-hemmende progestogen enthaltende hormonsubstitutions-therapie
BR9911116A (pt) Processo para tratar ou reduzir o risco de adquirir uma condição selecionada dentre o grupo consistindo de aterosclerose, câncer endometrial, câncer uterino, câncer ovariano, falta de lubrificação vaginal, e perda de massa muscular, composição farmacêutica, e, kit.
HU221169B1 (en) Use of estrogen and antiprogestin for producing pharmaceutical compositions useful in hormon replacement therapy and kit containing the same
Judd Efficacy of transdermal estradiol
NZ516502A (en) Administration of non-oral androgenic steroids to women having an elevated level of sex hormone binding globulin (SHBG)
CA2394165A1 (en) Drospirenone for hormone replacement therapy
US20120225853A1 (en) Hormone replacement therapy and depression
CZ298402B6 (cs) Použití farmaceutického prostredku obsahujícího estrogen a nomegestrolacelát
Wren et al. Differential clinical response to oestrogens after menopause
Speroff et al. Practical guidelines for postmenopausal hormone therapy
Stevenson Optimising delivery systems for HRT
US20160346298A1 (en) Hormone delivery system and method
Holloway Clinical update on hormone replacement therapy
JP2005527574A (ja) ホルモン補充療法におけるトリメゲストンと組み合わせた結合型エストロゲンの使用
Creatsas Possible Side-effects of Sexual Hormones
Yasar et al. Effect of misoprostol on bone mineral density in women with postmenopausal osteoporosis
MAIDA TAYLOR Estrogens: Estriol
Sismondi et al. HRT, breast and endometrial cancers: strategies and intervention options
Moghadam et al. Advances in menopausal hormonal therapy delivery systems: a comparative review

Legal Events

Date Code Title Description
FB Suspension of granting procedure